



Amanta Healthcare Limited announces Q3 & 9MFY26 Results

Consistent Revenue Momentum, 51% YoY Profit Growth in 9MFY26
Major Capacity Expansion in Progress

Ahmedabad, February 11th, 2026: Amanta Healthcare Limited (BSE: 544502 NSE: AMANTA) announced the unaudited financial results for the quarter ended December 31, 2025.

Rs. in Cr.	Q3FY26	Q3FY25	YoY %	9MFY26	9MFY25	YoY%
Revenue	74.49	67.8	9.84%	210.7	202.6	3.97%
Operating EBITDA	15.4	15.1	1.99%	44.9	42.3	6.06%
EBITDA Margin%	20.62%	22.21%	(159) bps	21.31%	20.89%	42 bps
PAT	4.7	4.3	8.12%	9.3	6.2	51.28%
PAT Margin%	6.21%	6.31%	(10) bps	4.43%	3.05%	139 bps

Q3& 9MFY26 Key Highlights:

- **Sustained revenue trajectory:**

Q3FY26 revenue stood at INR 75 cr, registering a 9.8% YoY growth, while 9MFY26 revenue reached INR 211 cr, marking a 3.97% YoY increase, reflecting steady demand and volume-led growth.

- **Operational discipline sustains EBITDA margins:**

Operating EBITDA for Q3FY26 came in at INR 15 cr with margins at 20.62%, while 9MFY26 EBITDA increased 6.06% YoY to INR 45 cr, with margins improving by 42 bps YoY to 21.31%, highlighting effective cost control and operational efficiency.

- **Profitability strengthens on robust execution:**

Net Profit for Q3FY26 rose to INR 5 cr, up 8.1% YoY, while 9MFY26 PAT grew 51.3% YoY to INR 9 cr, underscoring strong profitability momentum.

- **Improving earnings quality reflected in margins:**

Q3FY26 PAT margin stood at 6.21%, while 9MFY26 PAT margin expanded by 139 bps YoY to 4.43%, driven by operating leverage and margin normalization.

Commenting on the performance for the quarter, Bhavesh Patel, Chairman & Managing Director, Amanta Healthcare Limited said,

“We have reported a robust performance during the nine months of FY26, even as we undertook focused initiatives to support future growth. These initiatives are expected to start reflecting in our performance in the coming quarters. Our Revenue increased 3.97% YoY to ₹210.7 crore, while EBITDA grew 6.06% YoY to ₹44.9 crore. Operational PAT rose 51.3% YoY to ₹9.3 crore, with Operating PAT margins expanding by 139 bps to 4.43%, underscoring the strength and resilience of our business model.

On a quarterly basis, revenue stood at ₹74.5 crore, with EBITDA of ₹15.4 crore, while Operational PAT increased 8.1% YoY to ₹4.6 crore.

We are executing a focused growth roadmap driven by wallet share expansion in complex therapies, scaling high-margin SteriPort and SVP capacities, and structural cost optimization through green energy initiatives - positioning the company for accelerated growth from Q4 onwards.”

ABOUT AMANTA HEALTHCARE LIMITED

Amanta, a pharmaceutical company engaged in development, manufacturing, and marketing of sterile liquid products, including both large and small volume parenteral (LVPs and SVPs). Using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies, the Company serves six therapeutic segments with products such as IV fluids, diluents, ophthalmic and respiratory care, and irrigation solutions. The packaging includes a wide range of closure systems and container volumes from 2 ml to 1000 ml. Amanta is led by experienced Management including our Promoter & CMD – Mr. Bhavesh Patel, a Mechanical Engineer and master’s degree in management with more than 30 years of experience.

For more information, please visit: www.amanta.co.in

Company contact	Investor Relations Team
Email: cs@amanta.co.in , Tel: 079 6777 7600 Amanta Healthcare Ltd. 8th Floor, Shaligram Corporates, C. J. Marg, Ambli, Ahmedabad 380058 Gujarat, India	Soumya Chhajer Email- soumya@goindiaadvisors.com Mobile: +91-8619707750